XML 106 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative and Other Relationships (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Co-promotion profit sharing formula As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:
After LUNSUMIO Approval until the First Threshold Date37.5 %
After First Threshold Date until the Second Threshold Date35.0 %
After Second Threshold Date30.0 %
Pretax profit sharing formula Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:
Until Second GAZYVA Threshold Date37.5 %
After Second GAZYVA Threshold Date35.0 %
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Years Ended December 31,
(In millions)202320222021
Royalty revenue on sales of OCREVUS$1,266.2 $1,136.3 $991.7 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO(1)
409.4 547.0 647.7 
Other revenue from anti-CD20 therapeutic programs14.0 17.2 19.1 
Total revenue from anti-CD20 therapeutic programs$1,689.6 $1,700.5 $1,658.5 
(1) LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.
Revenue from anti-CD20 therapeutic programs is summarized as follows:
 For the Years Ended December 31,
(In millions)202320222021
Royalty revenue on sales of OCREVUS$1,266.2 $1,136.3 $991.7 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO(1)
409.4 547.0 647.7 
Other revenue from anti-CD20 therapeutic programs14.0 17.2 19.1 
Total revenue from anti-CD20 therapeutic programs$1,689.6 $1,700.5 $1,658.5 
(1) LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.
Summary of activity related to BAN2401 and Elenbecestat collaboration
A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:
 For the Years Ended December 31,
(In millions)202320222021
Total development expense incurred by the collaboration related to the advancement of LEQEMBI$371.9 $347.2 $323.0 
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our consolidated statements of income186.0 173.6 161.5 
Total sales and marketing expense incurred by the LEQEMBI Collaboration304.4 104.6 27.2 
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income152.2 52.3 13.6 
Summary of activity related to Aducanumab collaboration
A summary of development expense, sales and marketing expense and milestone payments related to our initial ADUHELM Collaboration Agreement is as follows:
For the Year Ended December 31,
(In millions)20222021
Total ADUHELM Collaboration development expense$149.4 $183.7 
Biogen's share of the ADUHELM Collaboration development expense reflected in research and development expense in our consolidated statements of income82.2 101.1 
Total sales and marketing expense incurred by the ADUHELM Collaboration134.2 562.3 
Biogen's share of the ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our consolidated statements of income71.5 301.4 
Total ADUHELM Collaboration third party milestones— 100.0 
Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing/(loss reimbursement) in our consolidated statements of income— 45 
Summary of activity related to the UCB collaboration
A summary of development expense related to the UCB collaboration agreement is as follows:
For the Years Ended December 31,
(In millions)202320222021
Total UCB collaboration development expense$60.7 $68.0 $84.2 
Biogen's share of the UCB collaboration development expense reflected in research and development expense in our consolidated statements of income30.3 34.0 42.1 
Summary of Activity Related to Sage Therapeutics
A summary of development and sales and marketing expense related to the Sage collaboration is as follows:
For the Years Ended December 31,
(In millions)202320222021
Total Sage collaboration development expense$176.7 $173.3 $167.7 
Biogen's share of the Sage collaboration development expense reflected in research and development expense in our consolidated statements of income88.3 86.7 83.8 
Total sales and marketing expense incurred by the Sage collaboration187.0 109.9 36.4 
Biogen's share of the Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our consolidated statements of income93.5 55.0 18.2 
Summary of Activity Related to Denali Therapeutics Collaboration
A summary of development expense related to the Denali collaboration is as follows:
For the Years Ended December 31,
(In millions)202320222021
Total Denali collaboration development expense$65.0 $75.1 $42.5 
Biogen's share of the Denali collaboration development expense reflected in research and development expense in our consolidated statements of income39.0 43.8 25.5 
Summary of Activity Related to Sangamo Therapeutics
A summary of development expense related to the Sangamo collaboration is as follows:
For the Years Ended December 31,
(In millions)202320222021
Total Sangamo collaboration development expense$4.1 $19.1 $22.7 
Biogen's share of the Sangamo collaboration development expense reflected in research and development expense in our consolidated statements of income2.4 12.1 14.6